Technology ID
TAB-2937
Real-time RT-PCR assay for Detection of Live Attenuated Influenza Vaccine for A and B Viruses
E-Numbers
E-560-2013-0
Lead Inventor
Shu, Bo (CDC)
Co-Inventors
Lindstrom, Stephen (CDC)
Wu, Kai-Hui (CDC)
Berman, LaShondra (CDC)
Warnes, Christine (CDC)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
In vivo data available (human)
Research Products
Research Equipment
Lead IC
CDC
ICs
CDC
Upon intranasal vaccination, live attenuated influenza vaccine (LAIV) viruses may replicate within the nose for several days. Current clinical diagnostic tests cannot distinguish between LAIV viruses and multiple influenza viruses in recently inoculated patients that present with respiratory symptoms. This poses a problem for the diagnosis and treatment of patients with respiratory symptoms, as these symptoms may not be caused by influenza. CDC researchers have developed a real-time RT-PCR assay to detect the presence of LAIV viruses. This test is rapid, accurate, and provides diagnostic data about whether patient respiratory symptoms are due to wild-type influenza or LAIV viruses. Detection of LAIV viruses with this assay will allow practitioners to investigate other pathogens as causative agents for a patient's respiratory symptoms.
Commercial Applications
- Diagnostic assay for the discrimination of LAIV A and B viruses from the influenza virus.
Competitive Advantages
- Ablility to distinguish between LAIV viruses A/B and influenza in patients with respiratory symptoms, thereby allowing for the pursuit of other potential pathogens (if symptoms are caused by LAIV instead of influenza).
- Can detect LAIV A and B viruses.
Licensing Contact: